EUVIMEDEUVIMED entdecken
Open Access

Amyloid-β positivity is less prevalent in cognitively unimpaired KLOTHO KL-VS heterozygotes

Noah Cook iD, Ira Driscoll iD, Julian M Gaitán, Matthew Glittenberg, Tobey J Betthauser iD, Cynthia M Carlsson iD, Sterling C Johnson, Sanjay Asthana, Henrik Zetterberg, Kaj Blennow, Gwendlyn Kollmorgen, Clara Quijano-Rubio und 2 weitere

Journal of Alzheimer’s Disease · 2024

DOI: 10.1177/13872877241289785 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Noah Cook und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, US…. Hauptthemen laut MEDLINE: Klotho Proteins, Glucuronidase, Amyloid beta-Peptides, Heterozygote. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NCATS NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Klotho, encoded by the KLOTHO gene, is an anti-aging and neuroprotective protein. KLOTHO KL-VS heterozygosity (KL-VS HET ) is hypothesized to be protective against the accumulation of Alzheimer's disease (AD) neuropathological hallmarks (amyloid-β (Aβ) and tau).

Objective

We examine whether being positive for Aβ (A+) or tau (T+), or A/T joint status [positive for Aβ (A + T-), tau (A-T+), both (A + T+) or neither (A-T-)] vary by KL-VS and whether serum klotho protein levels vary based on A+, T+, or A/T status in a cohort enriched for AD risk.

Methods

The sample consisted of 704 cognitively unimpaired, late middle-aged, and older adults; Mean Age (SD) = 64.9(8.3). Serum klotho was available for a sub-sample of 396 participants; Mean Age (SD) = 66.8(7.4). Covariate-adjusted logistic regression examined whether A + or T+, and multinomial regression examined whether A/T status, vary by KL-VS genotype. Covariate-adjusted linear regression examined whether serum klotho levels differ based on A+, T+, or A/T status.

Results

A+ prevalence was lower in KL-VS HET ( p = 0.05), with no differences in T + prevalence ( p = 0.52). KL-VS HET also had marginally lower odds of being A + T- ( p = 0.07). Serum klotho levels did not differ based on A+, T+, or A/T status (all ps ≥ 0.40).

Conclusions

KL-VS HET is associated with lower odds of being positive for Aβ, regardless of whether one is also positive for tau. Conversely, the likelihood of being tau positive did not differ based on KL-VS genotype. Our findings add to the growing KLOTHO literature and suggests the need for further research focused on understanding the mechanisms underlying KL-VS-related putative resilience to AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klotho ProteinsGlucuronidaseAmyloid beta-PeptidesHeterozygotetau ProteinsAlzheimer DiseaseHumansMaleFemaleAgedMiddle AgedCognitionAged, 80 and overCohort Studies

Stichwörter der Autor:innen

Alzheimer's diseasebiomarkerscerebrospinal fluidklothopositron emission tomographytau

Substanzen

Klotho ProteinsGlucuronidaseAmyloid beta-Peptidestau Proteins

Autor:innen und Institutionen

  • Department of Medicine and Alzheimer's Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA.
  • Department of Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
  • Wisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
  • Geriatric Research Education and Clinical Center, William S. Middleton VA Hospital, Madison, WI, USA.
  • Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
  • Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.

ORCID-Profile: Noah Cook, Ira Driscoll, Tobey J Betthauser, Cynthia M Carlsson

Förderung

  • NIA NIH HHS
  • NCATS NIH HHS
  • NINDS NIH HHS
  • NCRR NIH HHS
  • National Institute on Aging
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Cook, N., Driscoll, I., Gaitán, J. M., Glittenberg, M., Betthauser, T. J., Carlsson, C. M., Johnson, S. C., Asthana, S., Zetterberg, H., Blennow, K., Kollmorgen, G., Quijano-Rubio, C., Dubal, D. B., & Okonkwo, O. C. (2024). Amyloid-β positivity is less prevalent in cognitively unimpaired KLOTHO KL-VS heterozygotes. Journal of Alzheimer’s Disease. https://doi.org/10.1177/13872877241289785

Vancouver

Cook N, Driscoll I, Gaitán JM, Glittenberg M, Betthauser TJ, Carlsson CM, et al. Amyloid-β positivity is less prevalent in cognitively unimpaired KLOTHO KL-VS heterozygotes. Journal of Alzheimer’s Disease. 2024. doi:10.1177/13872877241289785

BibTeX
@article{Cook2024,
  author = {Cook, Noah and Driscoll, Ira and Gaitán, Julian M and Glittenberg, Matthew and Betthauser, Tobey J and Carlsson, Cynthia M and Johnson, Sterling C and Asthana, Sanjay and Zetterberg, Henrik and Blennow, Kaj and Kollmorgen, Gwendlyn and Quijano-Rubio, Clara and Dubal, Dena B and Okonkwo, Ozioma C},
  title = {Amyloid-β positivity is less prevalent in cognitively unimpaired KLOTHO KL-VS heterozygotes},
  journal = {Journal of Alzheimer’s Disease},
  year = {2024},
  doi = {10.1177/13872877241289785}
}
Kostenlos starten →